These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31865273)

  • 21. Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2019 Nov; 266(11):2672-2677. PubMed ID: 31312958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis.
    Fragoso YD; Adoni T; Alves-Leon SV; Apostolos-Pereira SL; Araujo YR; Becker J; Brooks JBB; Correa EC; Damasceno A; Damasceno CAA; Ferreira MLB; Gama PDD; Gama RADD; Gomes S; Goncalves MVM; Grzesiuk AK; Machado SCN; Matta APDC; Mendes MF; Ribeiro TAGJ; Rocha CFD; Ruocco HH; Sato H; Simm RF; Tauil CB; Vasconcelos CCF; Vieira VLF
    Expert Rev Clin Pharmacol; 2016 Apr; 9(4):541-546. PubMed ID: 26794493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    Ziemssen T; Lang M; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Lang S; Winkelmann VE; Ettle B; Schulze-Topphoff U;
    J Neurol; 2022 Jun; 269(6):3276-3285. PubMed ID: 34982201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness of fingolimod in a Portuguese real-world population.
    Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
    Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis.
    Vercellino M; Marasciulo S; Ricotti E; Rolando A; Bosa C; Garelli P; Gallina V; Vaula G; Calvo A; Cavalla P
    Mult Scler; 2024 Oct; ():13524585241284846. PubMed ID: 39373183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapses in patients treated with fingolimod after previous exposure to natalizumab.
    Comi G; Gold R; Dahlke F; Sinha A; von Rosenstiel P; Tomic D; Kappos L
    Mult Scler; 2015 May; 21(6):786-90. PubMed ID: 25257618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
    Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
    CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.
    Boziki M; Bakirtzis C; Giantzi V; Sintila SA; Kallivoulos S; Afrantou T; Nikolaidis I; Ioannidis P; Karapanayiotides T; Koutroulou I; Parissis D; Grigoriadis N
    Front Neurol; 2021; 12():699844. PubMed ID: 34497577
    [No Abstract]   [Full Text] [Related]  

  • 30. Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    Bigaut K; Kremer L; Fabacher T; Ahle G; Goudot M; Fleury M; Gaultier C; Courtois S; Collongues N; de Seze J
    J Neurol; 2022 Jun; 269(6):3295-3300. PubMed ID: 34982200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A longitudinal real-life comparison study of natalizumab and fingolimod.
    Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
    Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
    Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
    Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
    Pfeuffer S; Schmidt R; Straeten FA; Pul R; Kleinschnitz C; Wieshuber M; Lee DH; Linker RA; Doerck S; Straeten V; Windhagen S; Pawlitzki M; Aufenberg C; Lang M; Eienbroeker C; Tackenberg B; Limmroth V; Wildemann B; Haas J; Klotz L; Wiendl H; Ruck T; Meuth SG
    J Neurol; 2019 Jan; 266(1):165-173. PubMed ID: 30446966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.
    Fragoso YD; Alves-Leon SV; Becker J; Brooks JB; Correa EC; Damasceno A; Gama PD; Gama RA; Matta AP; Maciel EP; Winckler TC
    Arq Neuropsiquiatr; 2016 Aug; 74(8):650-2. PubMed ID: 27556377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
    Butzkueven H; Kappos L; Wiendl H; Trojano M; Spelman T; Chang I; Kasliwal R; Jaitly S; Campbell N; Ho PR; Licata S;
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):660-668. PubMed ID: 32234967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis.
    Graves JS; Thomas M; Li J; Shah AR; Goodyear A; Lange MR; Schmidli H; Häring DA; Friede T; Gärtner J
    Ther Adv Neurol Disord; 2022; 15():17562864211070449. PubMed ID: 35514529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis.
    Cofield SS; Fox RJ; Tyry T; Salter AR; Campagnolo D
    Int J MS Care; 2016; 18(5):230-238. PubMed ID: 27803638
    [No Abstract]   [Full Text] [Related]  

  • 39. Real-life clinical use of natalizumab and fingolimod in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T
    Acta Neurol Scand; 2018 Feb; 137(2):181-187. PubMed ID: 29159801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis.
    Fakih AU; Sahraian MA; Paybast S; Naser Moghadasi A
    Mult Scler Relat Disord; 2023 Mar; 71():104564. PubMed ID: 36863084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.